UNLABELLED: Obstructive cholestasis induces liver injury, postoperative complications, and mortality after surgery. Adaptive control of cholestasis, including bile salt homeostasis, is necessary for recovery and survival. Peripheral serotonin is a cytoprotective neurotransmitter also associated with liver regeneration. The effect of serotonin on cholestatic liver injury is not known. Therefore, we tested whether serotonin affects the severity of cholestatic liver injury. We induced cholestasis by ligation of the bile duct (BDL) in either wild-type (WT) mice or mice lacking peripheral serotonin (Tph1(-/-) and immune thrombocytopenic [ITP] mice). Liver injury was assessed by the levels of plasma aspartate aminotransferase (AST), alanine aminotransferase (ALT) and tissue necrosis. Bile salt-regulating genes were measured by quantitative polymerase chain reaction and confirmed by western blotting and immunohistochemistry. Tph1(-/-) mice displayed higher levels of plasma AST, ALT, bile salts, and hepatic necrosis after 3 days of BDL than WT mice. Likewise, liver injury was disproportional in ITP mice. Moreover, severe cholestatic complications and mortality after prolonged BDL were increased in Tph1(-/-) mice. Despite the elevation in toxic bile salts, expression of genes involved in bile salt homeostasis and detoxification were not affected in Tph1(-/-) livers. In contrast, the bile salt reabsorption transporters Ostα and Ostβ were up-regulated in the kidneys of Tph1(-/-) mice, along with a decrease in urinary bile salt excretion. Serotonin reloading of Tph1(-/-) mice reversed this phenotype, resulting in a reduction of circulating bile salts and liver injury. CONCLUSION: We propose a physiological function of serotonin is to ameliorate liver injury and stabilize the bile salt pool through adaptation of renal transporters in cholestasis.
UNLABELLED: Obstructive cholestasis induces liver injury, postoperative complications, and mortality after surgery. Adaptive control of cholestasis, including bile salt homeostasis, is necessary for recovery and survival. Peripheral serotonin is a cytoprotective neurotransmitter also associated with liver regeneration. The effect of serotonin on cholestatic liver injury is not known. Therefore, we tested whether serotonin affects the severity of cholestatic liver injury. We induced cholestasis by ligation of the bile duct (BDL) in either wild-type (WT) mice or mice lacking peripheral serotonin (Tph1(-/-) and immune thrombocytopenic [ITP] mice). Liver injury was assessed by the levels of plasma aspartate aminotransferase (AST), alanine aminotransferase (ALT) and tissue necrosis. Bile salt-regulating genes were measured by quantitative polymerase chain reaction and confirmed by western blotting and immunohistochemistry. Tph1(-/-) mice displayed higher levels of plasma AST, ALT, bile salts, and hepatic necrosis after 3 days of BDL than WT mice. Likewise, liver injury was disproportional in ITPmice. Moreover, severe cholestatic complications and mortality after prolonged BDL were increased in Tph1(-/-) mice. Despite the elevation in toxic bile salts, expression of genes involved in bile salt homeostasis and detoxification were not affected in Tph1(-/-) livers. In contrast, the bile salt reabsorption transporters Ostα and Ostβ were up-regulated in the kidneys of Tph1(-/-) mice, along with a decrease in urinary bile salt excretion. Serotonin reloading of Tph1(-/-) mice reversed this phenotype, resulting in a reduction of circulating bile salts and liver injury. CONCLUSION: We propose a physiological function of serotonin is to ameliorate liver injury and stabilize the bile salt pool through adaptation of renal transporters in cholestasis.
Authors: Kara Gross Margolis; Jennifer Vittorio; Maria Talavera; Karen Gluck; Zhishan Li; Alina Iuga; Korey Stevanovic; Virginia Saurman; Narek Israelyan; Martha G Welch; Michael D Gershon Journal: Am J Physiol Gastrointest Liver Physiol Date: 2017-08-03 Impact factor: 4.052
Authors: Lirui Wang; Phillipp Hartmann; Michael Haimerl; Sai P Bathena; Christopher Sjöwall; Sven Almer; Yazen Alnouti; Alan F Hofmann; Bernd Schnabl Journal: J Hepatol Date: 2014-02-19 Impact factor: 25.083
Authors: Benjamin L Woolbright; Mitchell R McGill; Vincent S Staggs; Robert D Winefield; Parviz Gholami; Mojtaba Olyaee; Matthew R Sharpe; Steven C Curry; William M Lee; Hartmut Jaeschke Journal: Toxicol Sci Date: 2014-09-19 Impact factor: 4.849
Authors: N Joshi; A K Kopec; K M O'Brien; K L Towery; H Cline-Fedewa; K J Williams; B L Copple; M J Flick; J P Luyendyk Journal: J Thromb Haemost Date: 2014-12-11 Impact factor: 5.824
Authors: Michael Camilleri; Andrea Shin; Irene Busciglio; Paula Carlson; Andres Acosta; Adil E Bharucha; Duane Burton; Jesse Lamsam; Alan Lueke; Leslie J Donato; Alan R Zinsmeister Journal: Am J Physiol Gastrointest Liver Physiol Date: 2014-07-10 Impact factor: 4.052
Authors: Ahmed Ghallab; Reham Hassan; Ute Hofmann; Adrian Friebel; Zaynab Hobloss; Lisa Brackhagen; Brigitte Begher-Tibbe; Maiju Myllys; Joerg Reinders; Nina Overbeck; Selahaddin Sezgin; Sebastian Zühlke; Abdel-Latif Seddek; Walaa Murad; Tim Brecklinghaus; Franziska Kappenberg; Jörg Rahnenführer; Daniela González; Christopher Goldring; Ian M Copple; Rosemarie Marchan; Thomas Longerich; Mihael Vucur; Tom Luedde; Stephan Urban; Ali Canbay; Thomas Schreiter; Michael Trauner; Jephte Y Akakpo; Mojtaba Olyaee; Steven C Curry; Jan-Peter Sowa; Hartmut Jaeschke; Stefan Hoehme; Jan G Hengstler Journal: J Hepatol Date: 2022-02-05 Impact factor: 30.083